1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?

 
• By Alaric DeArment

Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.

Cancer cells on scientific background.3d illustration
Gilead said the FDA had placed a partial hold on its trials testing magrolimab with Vidaza • Source: Shutterstock

Gilead Sciences, Inc. is keeping mum about what prompted a partial clinical hold on its program to develop magrolimab in combination with Bristol Myers Squibb Company’s Vidaza (azacitidine), apart from an imbalance in adverse events. But whatever the culprit, further delays in the program caused by the hold could erode Gilead’s lead in an increasingly crowded field of CD47-targeting drugs.

Gilead said 25 January that the US Food and Drug Administration placed a partial clinical hold on studies evaluating magrolimab/Vidaza...

More from Clinical Trials

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

More from R&D

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.